Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Archives of Osteoporosis
Published in: Archives of Osteoporosis 1-2/2011

01-12-2011 | Original Article

New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis—CEE”, November 2009, Budapest, Hungary

Authors: Péter Lakatos, Ádám Balogh, Edward Czerwinski, Hans P. Dimai, Didier Hans, Gerold Holzer, Roman S. Lorenc, Vladimir Palicka, Barbara Obermayer-Pietsch, Jan Stepan, István Takács, Heinrich Resch, on behalf of the Members of the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)”

Published in: Archives of Osteoporosis | Issue 1-2/2011

Login to get access

Abstract

Introduction

In November 2009, the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)” was held in Budapest, Hungary. The conference aimed to tackle issues regarding osteoporosis management in CEE identified during the second CEE summit in 2008 and to agree on approaches that allow most efficient and cost-effective diagnosis and therapy of osteoporosis in CEE countries in the future.

Discussion

The following topics were covered: past year experience from FRAX® implementation into local diagnostic algorithms; causes of secondary osteoporosis as a FRAX® risk factor; bone turnover markers to estimate bone loss, fracture risk, or monitor therapies; role of quantitative ultrasound in osteoporosis management; compliance and economical aspects of osteoporosis; and osteoporosis and genetics. Consensus and recommendations developed on these topics are summarised in the present progress report.

Conclusion

Lectures on up-to-date data of topical interest, the distinct regional provenances of the participants, a special focus on practical aspects, intense mutual exchange of individual experiences, strong interest in cross-border cooperations, as well as the readiness to learn from each other considerably contributed to the establishment of these recommendations. The “4th Summit on Osteoporosis—CEE” held in Prague, Czech Republic, in December 2010 will reveal whether these recommendations prove of value when implemented in the clinical routine or whether further improvements are still required.
Literature
1.
O’Neil TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018CrossRef
2.
Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79:269–280PubMedCrossRef
3.
Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26PubMedCrossRef
4.
Lorenc RS, Resch H (2009) Management of osteoporosis in Central and Eastern Europe (CEE): conclusions of the “2nd Summit on Osteoporosis—CEE”, 21–22 November 2008, Warsaw, Poland. Arch Osteoporos 4:1–8PubMedCrossRef
5.
Franek E, Karczmarewicz E, Misiorowski W et al (2009) Treatment benefits evaluation in osteoporosis—position of the Summit International Conference on Osteoporosis—Central Eastern Europe held 21–22 November 2008, Warsaw, Poland. Bone 44:S374–S375CrossRef
6.
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMedCrossRef
7.
McCloskey EV, Johansson H, Oden A, Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX® algorithm. Curr Osteoporos Rep 7:77–83PubMedCrossRef
8.
Kanis JA, McCloskey EV, Johansson H, Oden A, Ström O, Borgström F (2010) Development and use of FRAX® in osteoporosis. Osteoporos Int 21((Suppl 2)):S407–S413PubMedCrossRef
9.
Pluskiewicz W, Adamczyk P, Franek E, Leszczynski P, Sewerynek E, Wichrowska H, Napiorkowska L, Kostyk T, Stuss M, Stepien-Klos W, Golba KS, Drozdzowska B (2010) Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX® and nomogram by Nguyen et al.—conformity between methods and their clinical utility. Bone 46:1661–1667PubMedCrossRef
10.
Tałałaj M (2009) Bone fracture risk at secondary osteoporoses. Third Central European Congress on Osteoporosis and Osteoarthritis, Krakow, Poland. Abstract L33
11.
Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323PubMedCrossRef
12.
Genant HK, Delmas PD, Chen P, Jiang Y, Eriksen EF, Dalsky GP, Marcus R, San Martin J (2007) Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporos Int 18:69–76PubMedCrossRef
13.
Chen P, Krege JH, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos E, Kreiger N, Olszynski WP, Josse RG, Goltzman D (2009) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. J Bone Miner Res 24:495–502PubMedCrossRef
14.
15.
Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:155–162PubMedCrossRef
16.
van Staa TP, Leufkens HG, Cooper C (1991) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRef
17.
Meenan RF, Kazis LE, Anthony JM, Wallin BA (1991) The clinical and health status of patients with recent-onset rheumatoid arthritis. Arthritis Rheum 34:761–765PubMedCrossRef
18.
Kanis JA, Burlet N, Cooper C, Delmas PD, ReginsterJ-Y BF, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef
19.
Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762–2767PubMedCrossRef
20.
Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970PubMedCrossRef
21.
Stepan JJ, Zikán V (2003) Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 336:49–55PubMedCrossRef
22.
Holzer G, Noske H, Lang T, Holzer L, Willinger U (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13–17PubMedCrossRef
23.
Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F (2005) BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 16:943–952PubMedCrossRef
24.
Hellman J, Käkönen SM, Matikainen MT, Karp M, Lövgren T, Väänänen HK, Pettersson K (1996) Epitope mapping of nine monoclonal antibodies against osteocalcin: combinations into two-site assays affect both assay specificity and sample stability. J Bone Miner Res 11:1165–1175PubMedCrossRef
25.
Seibel MJ, Lang M, Geilenkeuser WJ (2001) Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 47:1443–1450PubMed
26.
Faulkner KG, von Stetten E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343–350PubMedCrossRef
27.
Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15PubMedCrossRef
28.
29.
30.
Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460PubMedCrossRef
31.
Seeman E, Compston J, Adachi J, Brandi ML, Cooper C, Dawson-Hughes B, Jönsson B, Pols H, Cramer JA (2007) Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 18:711–719PubMedCrossRef
32.
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef
33.
Ström O, Borgström F, Kanis JA, Jönsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23–34PubMedCrossRef
34.
Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916PubMedCrossRef
35.
Rivadeneira F, Styrkársdottir U, Estrada K et al (2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 41:1199–1206PubMedCrossRef
36.
Little RD, Carulli JP, Del Mastro RG et al (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70:11–19PubMedCrossRef
37.
Gong Y, Slee RB, Fukai N et al (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513–523PubMedCrossRef
38.
Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72:207–214PubMedCrossRef
39.
van Meurs JB, Trikalinos TA, Ralston SH et al (2008) Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 299:1277–1290PubMedCrossRef
Metadata
Title
New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis—CEE”, November 2009, Budapest, Hungary
Authors
Péter Lakatos
Ádám Balogh
Edward Czerwinski
Hans P. Dimai
Didier Hans
Gerold Holzer
Roman S. Lorenc
Vladimir Palicka
Barbara Obermayer-Pietsch
Jan Stepan
István Takács
Heinrich Resch
on behalf of the Members of the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)”
Publication date
01-12-2011
Publisher
Springer-Verlag
Published in
Archives of Osteoporosis / Issue 1-2/2011
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-010-0048-2

Other articles of this Issue 1-2/2011

Archives of Osteoporosis 1-2/2011 Go to the issue

Original Article

Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta

Original Article

Influence of menopause on mandibular bone quantity and quality in Japanese women receiving dental implants

Original Article

Normative calcaneal quantitative ultrasound data for the indigenous Shuar and non-Shuar Colonos of the Ecuadorian Amazon

Original Article

PRO-OSTEO Project (improving osteoporosis management in the acute hospital setting): a pilot single-centre study

Letter

A linear regression model can estimate hip fracture incidence

Case Report

Bone pain and extremely low bone mineral density due to severe vitamin D deficiency in celiac disease